5200 Illumina Way
About Illumina, Inc.
Illumina is improving the future of human health by unlocking the power of the genome. Our mission is everything to us. We are deeply passionate about what we do because we know we are solving problems that really matter. Our people and technology change lives by pioneering advancements in life sciences, oncology, reproductive health, agriculture, forensic genomics, and much more. Working in such critical fields requires industry-leading support, service, and scalability, and we strive to meet these challenges by collaborating across groups, business units, and locations. We are growing rapidly and looking for great talent to join Illumina.
We invite you to explore our career opportunities: https://www.illumina.com/company/careers.html
Jay T. Flatley - Executive Chairman
Francis deSouza - President & Chief Executive Officer
Garret Hampton, PhD - Executive Vice President, Clinical Genomics
Omead Ostadan - Executive Vice President, Operations, Products & Strategy
Marc Stapley - Executive Vice President & Chief Administrative Officer
Charles Dadswell - Senior Vice President & General Counsel
Mostafa Ronaghi, PhD - Senior Vice President & Chief Technology Officer
Sam Samad - Senior Vice President & Chief Financial Officer
Mark Van Oene - Senior Vice President & Chief Commercial Officer
Stock Symbol: ILMN
Stock Exchange: NASDAQ
Life at Illumina
712 articles with Illumina, Inc.
Illumina, Inc. today announced that it will issue results for third quarter 2018 following the close of market on Tuesday, October 23, 2018.
10/5/2018Guardant Health went on the Nasdaq yesterday under the symbol GH. Shares climbed almost 70 percent on the first day of trading, selling 12.5 million shares at $19 per share in the initial public offering (IPO).
Illumina Announces Conversion Period for 0% Convertible Senior Notes due 2019 and 0.5% Convertible Senior Notes due 2021
Illumina, Inc.. (Nasdaq: ILMN) (“Illumina” or the “Company”) today notified holders of its 0% Convertible Senior Notes due 2019 (the “2019 Notes”) and its 0.5% Convertible Senior Notes due 2021 (the “2021 Notes” and, together with the 2019 Notes, the “Notes”) that the Notes will become convertible into Illumina common stock at the option of the holders (the “Conversion Option”) beginning on October 1, 2018, and ending at the close of business on December 31, 2018.
Ilan Danieli, chief executive officer and co-founder of Precipio, a company with a liquid biopsy technology, took time to talk to BioSpace about the company and the economics of liquid biopsies.
Adds former Illumina operations team to develop and commercialize gene-editing technology
Illumina, Inc. today announced that its executives will be speaking at the following investor conference, and invited investors to participate via webcast.
Illumina, Inc. announced its intention to offer, subject to market and other conditions, approximately $650 million aggregate principal amount of convertible senior notes due 2023
Illumina, Inc. announced its financial results for the second quarter of fiscal year 2018.
NuProbe Global announced today the formation of its Scientific Advisory Board (SAB) with genomics pioneers George M. Church, Ph.D. and David R. Walt, Ph.D.
Recent studies in early diagnostics underline just how much focus medical technology companies are making on developing different modalities for very early cancer diagnosis. Here are just some recent examples.
Despite President Trump circling around semi-regularly to bash the pharmaceutical industry and drug prices, biotech stocks seem to be doing pretty well. The Nasdaq Biotechnology ETF, called the IBB, is up about 17 percent so far this year.
OrigiMed Collaborates with Illumina to Further Develop and Promote its Advanced Clinical Molecular Tumor Applications
OrigiMed announces an agreement with Illumina in Shanghai, China.
Illumina, Inc. announced that it will issue results for second quarter 2018 following the close of market on Monday, July 30, 2018.
It’s hard to believe 2018 is half over. There have been plenty of interesting and important stories in the biopharma space this year. Here’s a look at our top 10 stories so far, counting down from 10 to the number one story.
Both “rare cancers” and “sub-populations of cancers” present a challenge to companies conducting clinical trials—finding enough patients for those trials.
Illumina, Inc. announced that its executives will be speaking at the following investor conferences, and invited investors to participate via webcast.
For some time, the difference between a biotechnology company and a pharmaceutical company was straightforward. A biotechnology focused on developing drugs with a biological basis. Pharmaceutical companies focused on drugs with a chemical basis. But what about nanotechnology? Is that biotechnology?
Edico’s DRAGEN® Bio-IT Platform Delivers Faster, Streamlined Output for Next-Generation Sequencing
Some accelerators come out of government and academic institutions, while others have specific big pharma backing. Many use a combination of all of the above, while some are private in nature linked to venture capital firms. Let’s look at some of the accelerators linked to big pharma.
Illumina, Inc. announced that its executives will be speaking at the following investor conference, and invites investors to participate via webcast.